Salvage Therapy With Low-Dose Ruxolitinib Leads to a Significant Improvement in Bronchiolitis Obliterans Syndrome in Patients With cGVHD After Allogeneic Hematopoietic Stem Cell Transplantation
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Salvage Therapy With Low-Dose Ruxolitinib Leads to a Significant Improvement in Bronchiolitis Obliterans Syndrome in Patients With cGVHD After Allogeneic Hematopoietic Stem Cell Transplantation
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-06-28
DOI
10.3389/fphar.2021.668825
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Evaluation of Ruxolitinib for Steroid-Refractory Chronic Graft-vs-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
- (2021) Hengwei Wu et al. JAMA Network Open
- Calcineurin Inhibitors Replacement by Ruxolitinib as Graft-versus-Host Disease Prophylaxis for Patients after Allogeneic Stem Cell Transplantation
- (2020) Yanmin Zhao et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Ruxolitinib combined with etanercept induce a rapid response to corticosteroid‐refractory severe acute graft vs host disease after allogeneic stem cell transplantation: Results of a multi‐center prospective study
- (2020) Yanmin Zhao et al. AMERICAN JOURNAL OF HEMATOLOGY
- Rapid versus gradual lung function decline in bronchiolitis obliterans syndrome after haematopoietic stem cell transplantation is associated with survival outcome
- (2019) Wang-Chun Kwok et al. RESPIROLOGY
- Ruxolitinib is an effective steroid sparing agent in children with steroid refractory/dependent bronchiolitis obliterans syndrome after allogenic hematopoietic cell transplantation
- (2019) Michelle Schoettler et al. BONE MARROW TRANSPLANTATION
- Ruxolitinib is an effective steroid sparing agent in bronchiolitis obliterans due to chronic graft-versus-host-disease
- (2019) Christopher Streiler et al. BONE MARROW TRANSPLANTATION
- Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study
- (2019) Virginia Escamilla Gómez et al. BONE MARROW TRANSPLANTATION
- Extracorporeal Photopheresis Improves Survival in Hematopoietic Cell Transplant Patients with Bronchiolitis Obliterans Syndrome without Significantly Impacting Measured Pulmonary Functions
- (2018) Mehrdad Hefazi et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease
- (2018) Hanna Jean Khoury et al. BONE MARROW TRANSPLANTATION
- Lung transplantation after allogeneic stem cell transplantation: a pan-European experience
- (2018) Mark Greer et al. EUROPEAN RESPIRATORY JOURNAL
- Repression of interferon β-regulated cytokines by the JAK1/2 inhibitor ruxolitinib in inflammatory human macrophages
- (2018) Marie Febvre-James et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Effect of Azithromycin on Airflow Decline–Free Survival After Allogeneic Hematopoietic Stem Cell Transplant
- (2017) Anne Bergeron et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Imatinib ameliorates bronchiolitis obliterans via inhibition of fibrocyte migration and differentiation
- (2017) Satoshi Watanabe et al. JOURNAL OF HEART AND LUNG TRANSPLANTATION
- Effect of Rituximab on Pulmonary Function in Bronchiolitis Obliterans Syndrome due to Graft-Versus-Host-Disease
- (2017) Kyle R. Brownback et al. LUNG
- Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation
- (2016) Kirsten M. Williams et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Therapeutic regulatory T-cell adoptive transfer ameliorates established murine chronic GVHD in a CXCR5-dependent manner
- (2016) Cameron McDonald-Hyman et al. BLOOD
- How I treat bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation
- (2016) Kirsten M. Williams BLOOD
- Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice
- (2016) Sophia Maschalidi et al. BLOOD
- Extracorporeal photopheresis as a new supportive therapy for bronchiolitis obliterans syndrome after allogeneic stem cell transplantation
- (2016) C Del Fante et al. BONE MARROW TRANSPLANTATION
- Budesonide/Formoterol for Bronchiolitis Obliterans after Hematopoietic Stem Cell Transplantation
- (2015) Anne Bergeron et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
- (2015) Madan H. Jagasia et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Imatinib for bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation
- (2015) S Watanabe et al. BONE MARROW TRANSPLANTATION
- JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms
- (2015) Kathrin Schönberg et al. CANCER RESEARCH
- Prognostic role of FEV1for survival in bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation
- (2015) Jee Hwan Ahn et al. CLINICAL TRANSPLANTATION
- Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey
- (2015) R Zeiser et al. LEUKEMIA
- Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease
- (2014) S. Spoerl et al. BLOOD
- Obliterative Bronchiolitis
- (2014) Alan F. Barker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pharmacologic Blockade of JAK1/JAK2 Reduces GvHD and Preserves the Graft-Versus-Leukemia Effect
- (2014) Jaebok Choi et al. PLoS One
- CXCR3 Ligands Are Associated with the Continuum of Diffuse Alveolar Damage to Chronic Lung Allograft Dysfunction
- (2013) Michael Y. Shino et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo
- (2013) A. Heine et al. BLOOD
- Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?
- (2013) A. Heine et al. BLOOD
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gram-Negative Infection and Bronchiectasis in Lung Transplant Recipients with Bronchiolitis Obliterans Syndrome
- (2012) Aaron Weiland et al. THORACIC AND CARDIOVASCULAR SURGEON
- Lung Transplantation for Bronchiolitis Obliterans After Allogeneic Hematopoietic Stem Cell Transplantation
- (2012) Ursula M. Vogl et al. TRANSPLANTATION
- Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for Subacute Pulmonary Dysfunction Following Allogeneic Stem Cell Transplantation
- (2011) Gregory A. Yanik et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Bronchiolitis Obliterans Syndrome Epidemiology after Allogeneic Hematopoietic Cell Transplantation
- (2010) Brandon K.C. Au et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Extracorporeal photopheresis in patients with refractory bronchiolitis obliterans developing after allo-SCT
- (2010) C E Lucid et al. BONE MARROW TRANSPLANTATION
- Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation—An Increasingly Recognized Manifestation of Chronic Graft-versus-Host Disease
- (2009) Jason W. Chien et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Bronchiolitis Obliterans After Allogeneic Hematopoietic Stem Cell Transplantation
- (2009) Kirsten M. Williams JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started